TAVR at 5 Years — Rematch or Swan Song for ...
Document type :
Article dans une revue scientifique: Article original
DOI :
Title :
TAVR at 5 Years — Rematch or Swan Song for Surgery?
Author(s) :
van Belle, Eric [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Journal title :
New England Journal of Medicine
Pages :
867-868
Publisher :
Massachusetts Medical Society
Publication date :
2020-02-27
ISSN :
0028-4793
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement ...
Show more >To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement in the long term. Makkar et al. examined this question and report in this issue of the Journal the 5-year outcomes of the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial, 2 which involved patients at intermediate surgical risk. A total of 2032 patients were stratified according to intended transfemoral or transthoracic access and randomly assigned to undergo TAVR with the second-generation balloon-expandable SAPIEN XT valve or surgical aortic-valve replacement. The trial showed that TAVR was noninferior to surgery with respect to the primary outcome of death from any cause or disabling stroke at 2 years. 3Show less >
Show more >To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement in the long term. Makkar et al. examined this question and report in this issue of the Journal the 5-year outcomes of the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial, 2 which involved patients at intermediate surgical risk. A total of 2032 patients were stratified according to intended transfemoral or transthoracic access and randomly assigned to undergo TAVR with the second-generation balloon-expandable SAPIEN XT valve or surgical aortic-valve replacement. The trial showed that TAVR was noninferior to surgery with respect to the primary outcome of death from any cause or disabling stroke at 2 years. 3Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Source :
Files
- document
- Open access
- Access the document
- Access%20provided%20by%20evb%20158.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- Access%20provided%20by%20evb%20158.pdf
- Open access
- Access the document